GREGORY L. WEAVER - 11 Nov 2024 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role
Chief Financial Officer
Signature
/s/ Vipin K. Garg, as Attorney-in-Fact
Issuer symbol
ALT
Transactions as of
11 Nov 2024
Net transactions value
$0
Form type
4
Filing time
12 Nov 2024, 16:50:52 UTC
Previous filing
17 Nov 2023
Next filing
14 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALT Stock Options (option to buy) Award $0 +225,000 $0.000000 225,000 11 Nov 2024 Common Stock, par value $0.0001 225,000 $7.35 Direct F1
transaction ALT Restricted Stock Units Award $0 +75,000 $0.000000 75,000 11 Nov 2024 Common Stock, par value $0.0001 75,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on November 11, 2025, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested
F3 The RSUs become vested over four (4) years with 25% of the shares vesting November 11, 2025, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.